Bioequivalence and Bioavailability Forum 05:17 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

The mysterious ρ -between or within studies [General Sta­tis­tics]

posted by d_labes - Berlin, Germany, 2018-02-11 19:36  - Posting: # 18400
Views: 7,366

Dear Nasty!

» So, for ρ=0.8 I get now
» > type1error.2TOST(CV=c(0.3, 0.25), n=122, theta1=c(0.8, 0.9),
» +                        theta2=c(1.25, 1/0.9), rho=0.8, details=TRUE)
» 1e+06 simulations. Time consumed (secs)
»    user  system elapsed
»  979.75   95.18 1115.72
»   Intersection null P(Type I Error) theta0 #1 theta0 #2
» 1      H_A01 n H_Ca        0.048904 0.8000000  0.953047
» 2      H_A02 n H_Ca        0.049193 1.2500000  1.056122
» 3      H_Aa n H_C01        0.049620 0.9709781  0.900000
» 4      H_Aa n H_C02        0.050024 1.0000000  1.111111
» ...
»
and inflation at 0.050024
Don't forget, that type1error.2TOST() is based on simulations now.
That's mainly because our (authors team of PowerTOST) brain is to small to derive an analytical solution. And simulations have an error. F.i. in setting the seed for the random number generator.
type1error.2TOST(CV=c(0.3, 0.25), n=122, theta1=c(0.8, 0.9), theta2=c(1.25, 1/0.9), rho=0.8, setseed=F)
[K1] 0.049977

In that light 0.050024 is of course not an alpha-inflation. As we know from theory, the IUT principle, the combination of two TOST via and assures alpha<=0.05. Thus interpret the result as 0.05. Full stop

» As I understand estimated from several datasets ρ is "between studies" ρ while in Power2TOST we need to use "within studies ρ".

I myself don't know what ρ or what value of ρ should be used. As I wrote above: It's under discussion now.

Thus if you or somebody else have an opinion or arguments: Give it to me.

Regards,

Detlew

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,154 posts in 4,080 threads, 1,308 registered users;
online 13 (0 registered, 13 guests [including 4 identified bots]).

One can show the following: given any rule, however “fundamental”
or “necessary” for science, there are always circumstances
when it is advisable not only to ignore the rule,
but to adopt its opposite.    Paul Feyerabend

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed